FDA Inspection
AstraZeneca Pharmaceuticals, LPAstraZeneca Pharmaceuticals, LP – FDA Inspection, Jan 30, 2017
Record Details
This FDA Inspection record concerns AstraZeneca Pharmaceuticals, LP, with an inspection on January 30, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · ee0ecf07-7650-4fab-bc7f-784e9249d085
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 998797
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of AstraZeneca Pharmaceuticals, LP
4| Date | Classification | Office | Project area |
|---|---|---|---|
| April 3, 2026 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 5, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 29, 2016 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 18, 2015 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for AstraZeneca Pharmaceuticals, LP
- FDA Inspection 1312298 - 2026-04-03
- FDA Inspection 1047488 - 2018-03-05
- FDA Inspection 963627 - 2016-03-29
- FDA Inspection 954660 - 2015-12-18
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.